Statin Treatment for Patients With Paroxysmal Atrial Fibrillation A J-RHYTHM Substudy
-
- Watanabe Eiichi
- Department of Cardiology, Fujita Health University School of Medicine
-
- Yamashita Takeshi
- The Cardiovascular Institute, Graduate School of Medicine, The University of Tokyo
-
- Suzuki Shinya
- Department of Clinical Epidemiology & Systems, Graduate School of Medicine, The University of Tokyo
-
- Saikawa Tetsunori
- Cardiovascular Science, Oita University
-
- Hirai Makoto
- Health Sciences, Nagoya University
-
- Yamazaki Tsutomu
- Department of Clinical Epidemiology & Systems, Graduate School of Medicine, The University of Tokyo
-
- Ohtsu Hiroshi
- Department of Clinical Trial Data Management, The University of Tokyo
-
- Ogawa Satoshi
- International University Health and Welfare, Mita Hospital
書誌事項
- タイトル別名
-
- A J-RHYTHM Substudy
この論文をさがす
説明
Recent clinical evidence and animal experiments support the belief that statins have beneficial effects on cardiovascular outcomes and prevention of atrial fibrillation (AF). We investigated whether the use of statins reduces the mortality, morbidity, and recurrence rate of AF in patients with paroxysmal AF. A post hoc analysis of the Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study was conducted.<br>Of the 823 patients with paroxysmal AF in the J-RHYTHM study, 101 (12.3%) were receiving a statin at baseline. Patients taking statins were older and more likely to have hypertension, dyslipidemia, coronary artery disease, and ischemic stroke compared to patients not taking statins. During a mean follow-up period of 19.3 months, 40 patients (5.5%) reached the primary endpoint (a composite of all-cause death, stroke, systemic embolism, major bleeding, and hospitalization for heart failure) and 140 patients (19.4%) experienced a recurrence of AF. Multivariate Cox proportional-hazard regression analysis revealed statin use was not associated with improved mortality and morbidity (hazard ratio [HR] 0.409, 95% confidence interval [CI] 0.113-1.482), or a decreased risk of AF recurrence (HR 0.662, 95% CI 0.299-1.466).<br>This analysis provides evidence that statin use did not affect clinical outcomes in patients with paroxysmal AF and emphasizes the need for randomized clinical trials defining more clearly the role of statins in treating AF.
収録刊行物
-
- International Heart Journal
-
International Heart Journal 52 (2), 103-106, 2011
一般社団法人 インターナショナル・ハート・ジャーナル刊行会
